Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of July 2025, with a specific reporting date of July 30, 2025. Haleon is a global leader in consumer health with a portfolio spanning six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company operates well-known brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics. This report is a notification of corporate governance changes rather than a financial results announcement.
Material Changes
The material change disclosed in this filing relates to corporate governance. Effective July 30, 2025, the Company announced the following Board Committee appointments:
- B láthnaid Berg appointed to the Audit & Risk Committee.
- Matt Shattock appointed to the Environmental & Social Sustainability Committee.
This notification was made in accordance with Listing Rule 6.4.6R of the UK Listing Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on performance, specific risks, contingencies, or unusual items. The document focuses solely on the administrative update regarding board committee composition.
Key Facts for Investor Verification
- Verify the effective date of the new board committee appointments (July 30, 2025).
- Confirm the specific roles of B láthnaid Berg and Matt Shattock within the Audit & Risk and Environmental & Social Sustainability Committees, respectively.
- Note that this filing contains no financial performance data for the period.